Merck KGaA: signs research agreement with Britain's 4D

(CercleFinance.com) - Britain's 4D said that it has signed a clinical trial collaboration with Germany's Merck and Pfizer to evaluate a combination of their drugs for the treatment of bladder cancer.


Under the deal, the Leeds-based pharmaceutical company, which makes drugs derived from the microbiome, will start a clinical trial this year to evaluate a combination of its experimental drug MRx0518 with Bavencio for the first-line maintenance therapy for patients with locally advanced or metastatic urothelial carcinoma that has not progressed after chemotherapy.

MRx0518 is an investigational oral pill that stimulates the body's immune system, directing it to produce cytokines and immune cells that are known to attack tumours.

Bavencio is being jointly developed and marketed by Merck and Pfizer.

Copyright (c) 2021 CercleFinance.com. All rights reserved.